


IFW



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))	Docket No. 015/03937
---	-------------------------

In Re Application Of: **Tami HAREL et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/804,560	March 18, 2004	Unknown	44909	3762	7075

Title: **BLOOD GLUCOSE LEVEL CONTROL**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.


37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
015/03937

In Re Application: Tami HAREL et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/804,560	March 18, 2004	Unknown	44909	3762	7075

Title: BLOOD GLUCOSE LEVEL CONTROL

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 03-3419 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450"

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Dated: August 12, 2004

Maier FENSTER, Reg. No. 41,016

William H. Dippert, Esq.
Reed Smith LLP
599 Lexington Avenue, 29th Floor
New York, NY 10022-7650

Tel: (212) 521-5400

cc:

015/03937



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In regard to the application of: Tami HAREL et al.

Serial No : 10/804,560

Group Art Unit: 3762

Filed : March 18, 2004

Examiner: Unknown

For : Blood Glucose Level Control

FIRST SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Hon. Commissioner of Patents and Trademarks

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Applicants respectfully direct the attention of the Examiner to art cited with respect to U.S. Application No. 10/804,560, which is a continuation-in-part under 35 U.S.C. §111(a) of PCT Application No. PCT/IL03/00736, which is a continuation-in-part under 35 U.S.C. §111(a) of U.S. Application No. 10/237,263, which is a continuation-in-part under 35 U.S.C. §111(a) of PCT Application No. PCT/IL00/00566. This application is also a continuation-in-part under 35 U.S.C. §111(a) of PCT Application No. PCT/IL00/00132, now U.S. Application No. 09/914,889. This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60/123,532 and U.S. Provisional Application No. 60/488,964.

The Examiner is respectfully requested to review and consider this art, in accordance with MPEP §2001.06, MPEP §1893.03(e) and MPEP §1893.03(g) and to indicate in the first office action that he has considered this art. Additionally, the Examiner is respectfully requested to cite those prior art publications mentioned in this application which the Examiner considers to be material or relevant to the present claims.

Further, in order to comply with discretionary regulations 37 C.F.R. §1.97 and §1.98, attached is an Equivalent to Form PTO-1449 listing the cited art. This art contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.


Applicants wish to point out that items 1-5 were cited in the parent U.S. Application No. 10/237,263. Copies of these items are not attached as they are available in the parent case.

In accordance with MPEP §609 it is requested that each document cited [including any mentioned in Applicants' specification which is not repeated on the attached (or prior) PTO-1449 form(s) or equivalent(s) thereof] be given thorough consideration and be cited of record in the prosecution history of the present application by initialing on the PTO-1449 form or its equivalent, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 C.F.R. §1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 C.F.R. §1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,
Tami HAREL et al.



Maier FENSTER,
Registration No. 41,016

August 12, 2004
William H. Dippert, Esq.
Reed Smith LLP
599 Lexington Avenue, 29th Floor
New York, NY 10022-7650

Tel: (212) 521-5400



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 015/03937	SERIAL NO. 10/804,560
	APPLICANT(S) Tami HAREL et al.	
	FILING March 18, 2004	GROUP 3762

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO


OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

1	GOMIS, A. et al.; "Oscillatory Patterns of Electrical Activity in Mouse Pancreatic Islets of Langerhans Recorded in Vivo;" July 1996; Pflügers Arch. – Eur. J. Physiol.; Vol. 432, No. 3; Pages 510-515
2	JAREMKO, J. et al.; "Advances Toward the Implantable Artificial Pancreas for Treatment of Diabetes;" March 1998; Diabetes Care; Vol. 21, No. 3; Pages 444-450
3	MAGNUS, G. et al.; "Model of β -Cell Mitochondrial Calcium Handling and Electrical Activity. II. Mitochondrial Variables;" April 1998; American Journal of Physiology; Vol. 274; Cell Physiol. 43; Pages C1174-C1184
4	NADAL, A. et al.; "Homologous and Heterologous Asynchronicity Between Identified α -, β - and δ -Cells Within Intact Islets of Langerhans in the Mouse;" May 1999; Journal of Physiology Vol. 517, Pt. 1; Pages 85-93
5	SORIA, B. et al.; "Cytosolic Calcium Oscillations and Insulin Release in Pancreatic Islets of Langerhans;" February 1998; Diabetes & Metabolism (Paris;) Vol. 24, No. 1; Pages 37-40

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Equivalent to Form PTO-1449

Patent and Trademark Office*U.S. DEPARTMENT OF COMMERCE



PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on August 16, 2004
Date


Geraldine Gress

Reed Smith LLP
599 Lexington Avenue
29th Floor
New York, New York 10022-7650
Tel: 212-521-5400; Fax: 212-521-5450

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Applicant: Tami Harel et al.
Serial No: 10/804,560
Filing Date: March 18, 2004
For: BLOOD GLUCOSE LEVEL CONTROL
Enclosures: (1) Transmittal Of Information Disclosure Statement (3 pages);
(2) First Supplementary Information Disclosure Statement (2 pages) w/IDS Citation (1 page);
(3) Acknowledgement Postcard.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.